Skip to main content
Signal8

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

$ZURAPress releaseMay 7, 2026, 7:30 AM ETRead the release

Zura Bio reported Q1 2026 financial results, highlighting a cash balance of $225.6 million that provides a runway into 2028 following a $144 million public offering in February. The company's lead program, tibulizumab, remains on track with Phase 2 trials in HS (TibuSHIELD) and systemic sclerosis (TibuSURE) targeting topline data readouts in Q4 2026 and H1 2027, respectively.

Key figures

Eps Beat
0
Revenue
0
Drug Name
tibulizumab (ZB-106)
Guidance
Cash runway expected to fund planned operations through at least the end of 2028
Revenue Yoy
0
Deal Value Usd
144000000
Phase Of Trial
Phase 2
Net loss
24200000
Ga expenses
10800000
Rd expenses
14700000
Cash position
225600000

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.